{"id":"W2891436279","doi":"10.1200/jco.2017.35.15_suppl.5553","title":"Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Tolerability; Bevacizumab; Neutropenia; Internal medicine; Adverse effect; Phases of clinical research; Pembrolizumab; Dosing; Oncology; Gastroenterology; Pharmacology; Chemotherapy; Cancer; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003366872,0.001940511,0.001695555,0.0004305834,0.0005103985,0.000987431,0.001024913,0.002052799,0.007765054],"category_scores_gemma":[0.001988162,0.0007113585,0.001556134,0.0003679756,0.0008618523,0.0008669453,0.0004385785,0.004166161,0.001670433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001583967,"about_ca_system_score_gemma":0.003015279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001242471,"about_ca_topic_score_gemma":0.003634992,"domain_scores_codex":[0.9989426,0.0005731569,0.00004612272,0.0001510556,0.0001526841,0.0001344608],"domain_scores_gemma":[0.9982662,0.000305467,0.00043421,0.0001409632,0.0001997649,0.0006534254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6712552,0.08461121,0.01128128,0.00168869,0.001786992,0.0007501075,0.0006027677,0.003729368,0.0852598,0.0006616564,0.02958611,0.1087869],"study_design_scores_gemma":[0.4414514,0.5165148,0.01369569,0.0001380457,0.0007960893,0.001016396,0.00006539958,0.001140892,0.009398066,0.0003139825,0.01540919,0.00006006275],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9611357,0.005536391,0.001934822,0.002135616,0.0003776739,0.008533998,0.009769819,0.0003080918,0.01026782],"genre_scores_gemma":[0.9545299,0.003813877,0.004455684,0.003806856,0.0005111011,0.006148729,0.01660056,0.0001313526,0.01000196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007765054,"threshold_uncertainty_score":0.02597672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07562984281282185,"score_gpt":0.4603788013918015,"score_spread":0.3847489585789797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}